(Q37951743)

25 August 2017

title

Towards new therapeutic approaches for malignant melanoma (English)

1 reference

25 August 2017

Ivan Pacheco

1

1 reference

25 August 2017

Cristina Buzea

series ordinal

2

1 reference

25 August 2017

Victor Tron

series ordinal

3

1 reference

25 August 2017

publication date

1 November 2011

1 reference

Expert Reviews in Molecular Medicine

25 August 2017

published in

1 reference

25 August 2017

volume

13

1 reference

25 August 2017

page(s)

e33

1 reference

Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Systematic review of medical treatment in melanoma: current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Immunotherapy of melanoma: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

IGFBP7 is not required for B-RAF-induced melanocyte senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Human endogenous retrovirus (HERV-K) reverse transcriptase as a breast cancer prognostic marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The role of human endogenous retroviruses in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The role of Bcl-2 family members in the progression of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Major response to imatinib mesylate in KIT-mutated melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Mutation-driven drug development in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

KIT as a therapeutic target in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Applications of genomics in melanoma oncogene discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Pharmacokinetics and pharmacodynamics of AZD6244 (ARRY-142886) in tumor-bearing nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeting BRAF in advanced melanoma: a first step toward manageable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

PLX4032: does it keep its promise for metastatic melanoma treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Cancer research. Melanoma drug vindicates targeted approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

B-RAF is a therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Systemic therapy for cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

BRAF, a target in melanoma: implications for solid tumor drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Resistance to BRAF inhibition in melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Stem and progenitor cell-mediated tumor selective gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Nanocarriers as an emerging platform for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Role of miRNAs in the progression of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Melanoma biology and new targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Potential clinical applications of siRNA technique: benefits and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeted delivery systems of small interfering RNA by systemic administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Use of liposomes as drug delivery vehicles for treatment of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Topical treatment with inhibitors of the phosphatidylinositol 3'-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Understanding signaling cascades in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

ERK and PI3K negatively regulate STAT-transcriptional activities in human melanoma cells: implications towards sensitization to apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Integrating BRAF/MEK inhibitors into combination therapy for melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Systemic therapy for metastatic malignant melanoma--from deeply disappointing to bright future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeting intracellular signaling pathways as a novel strategy in melanoma therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Identification of cells initiating human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Melanoma MicroRNA signature predicts post-recurrence survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Melanin pigmentation in mammalian skin and its hormonal regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

High-throughput miRNA profiling of human melanoma blood samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Cell line segregation during peripheral nervous system ontogeny.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The gene expression signatures of melanoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Natural selection on human microRNA binding sites inferred from SNP data

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Nonsolar occupational risk factors for cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Widespread changes in protein synthesis induced by microRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Melanoma epidemiology and trends.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

MicroRNA and cancer--focus on apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Early detection of endogenous retroviruses in chemically induced mouse cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Transcriptional activation of endogenous retroviral sequences in human epidermal keratinocytes by UVB irradiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Distinct roles for LINE-1 and HERV-K retroelements in cell proliferation, differentiation and tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

High frequency of BRAF mutations in nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Analysis of the genome to personalize therapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Cisplatin encapsulated in phosphatidylethanolamine liposomes enhances the in vitro cytotoxicity and in vivo intratumor drug accumulation against melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

A genome-based strategy uncovers frequent BRAF mutations in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Clinical phase II study of pegylated liposomal doxorubicin as second-line treatment in disseminated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

BRAF as therapeutic target in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The effect of thermotherapy using magnetic nanoparticles on rat malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Developing aptamers into therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Toward a molecular classification of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Driving in the melanoma landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Nanomaterials and nanoparticles: sources and toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Testing the divergent pathway hypothesis for melanoma: recent findings and future challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

pH-Responsive nanoparticles for drug delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Genetic epidemiology of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Role of sun exposure in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Cutaneous melanoma susceptibility and progression genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

A cell cycle regulator potentially involved in genesis of many tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Lipid-like materials for low-dose, in vivo gene silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

BRAF somatic mutations in malignant melanoma and melanocytic naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Epidemiology of invasive cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeting gold nanocages to cancer cells for photothermal destruction and drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Multimodal drug delivery using gold nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Remotely triggerable drug delivery systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Nanoparticles in medicine: therapeutic applications and developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Silencing livin gene by siRNA leads to apoptosis induction, cell cycle arrest, and proliferation inhibition in malignant melanoma LiBr cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Human cutaneous malignant melanoma as a model for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Targeted nanoparticles deliver siRNA to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Bcl-2 protein in 518A2 melanoma cells in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Simultaneous inhibition of MEK and CDK4 leads to potent apoptosis in human melanoma cells.

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Adjuvant therapy with high-dose interferon alpha 2b in patients with high-risk stage IIB/III melanoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Nanostructure-mediated drug delivery

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma

1 reference

https://api.crossref.org/works/10.1017%2FS146239941100202X

7 January 2021

10.1017/S146239941100202X

Identifiers

DOI

1 reference

25 August 2017

1 reference